Back to Search
Start Over
The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece.
- Source :
-
Infectious Diseases & Therapy . Sep2021, Vol. 10 Issue 3, p1081-1095. 15p. - Publication Year :
- 2021
-
Abstract
- In light of the accumulating evidence for survival benefit coming from the use of macrolides for community-acquired pneumonia (CAP), a group of experts from the field of internal medicine and infectious diseases frame a position statement on the use of macrolides for the management of bacterial CAP and for infection by the novel coronavirus (COVID-19). The statement is framed taking into consideration existing publications and own research experience. The main content of this statement is that the combination of one β-lactam and a macrolide should be the first treatment of choice for patients with severe bacterial CAP. Severity is assessed as scoring 2 or more points on the CURB65 scoring system of severity or as pneumonia severity index III to V or C-reactive protein more than 150 mg/l; the suggested macrolide is either azithromycin or clarithromycin. The experts also suggest that in COVID-19 pneumonia, the combination of one β-lactam and a macrolide should be reserved only when there is strong suspicion of bacterial co-infection. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 21938229
- Volume :
- 10
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Infectious Diseases & Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 151648426
- Full Text :
- https://doi.org/10.1007/s40121-021-00471-1